Fosphenytoin

Stephen Holliday, Paul Benfield and Greg Plosker ()

PharmacoEconomics, 1998, vol. 14, issue 6, 685-690

Abstract: Advantages and disadvantages of Fosphenytoin Advantages More rapid intravenous administration than phenytoin and no need for an in-line filter May be administered by intramuscular injection Lower potential for local tissue and cardiac toxicity than phenytoin Associated with less pain and phlebitis at the injection site, fewer reductions in infusion rate and fewer changes of administration site because of injection site complications than phenytoin Benefits in terms of ease of administration and improved tolerability vs phenytoin have pharmacoeconomic implications which may translate into an overall cost advantage Disadvantages Approximately 10-fold higher acquisition cost vs phenytoin ▲ Fosphenytoin is a parenterally administered prodrug of phenytoin, used in the treatment of patients with seizures. ▲ Advantages of fosphenytoin over phenytoin include more rapid intravenous administration, no need for an intravenous filter, and a lower potential for local tissue and cardiac toxicity. Unlike phenytoin, fosphenytoin may also be administered by intramuscular injection. ▲ Pharmacoeconomic data from a small study of patients with acute seizures in a US emergency department showed an overall cost advantage of fosphenytoin over phenytoin, despite a considerably greater acquisition cost of fosphenytoin. The main cost drivers for phenytoin therapy were treatment costs associated with adverse events. ▲ In view of the limited pharmacoeconomic data currently available, it is in the interests of individual institutions to conduct their own formal pharmacoeconomic studies applying local cost data and patterns of clinical practise to determine whether fosphenytoin should replace phenytoin on their formulary list. Copyright Adis International Limited 1998

Date: 1998
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-199814060-00008 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:14:y:1998:i:6:p:685-690

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-199814060-00008

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().